Dong-Yi Chen1, Szu-Heng Wang2, Chun-Tai Mao3, Ming-Lung Tsai1, Yu-Sheng Lin4, Chung-Chuan Chou1, Ming-Shien Wen1, Chun-Chieh Wang1, I-Chang Hsieh1, Kuo-Chun Hung1, Tien-Hsing Chen5. 1. Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. 2. Department of Medical Education, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. 3. Heart Failure Center, Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung, Taiwan; Chang Gung University College of Medicine, Taoyuan, Taiwan. 4. Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chiayi, Taiwan; Chang Gung University College of Medicine, Taoyuan, Taiwan. 5. Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan; Department of Cardiology, Chang Gung Memorial Hospital, Xiamen, China; Chang Gung University College of Medicine, Taoyuan, Taiwan. Electronic address: skyheart0826@gmail.com.
Abstract
BACKGROUND: The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabetic patients with chronic kidney disease (CKD) after acute myocardial infarction (AMI) are unclear. METHODS: We analyzed data from the Taiwan National Health Insurance Research Database between March 1st, 2009 and December 31st, 2011. A total of 1025 AMI patients with diabetes with chronic kidney disease were selected as the study cohort. The study evaluated the cardiovascular safety and efficacy of sitagliptin by comparing 205 subjects (20%) who use sitagliptin to 820 matched subjects (80%) who do not. The primary outcomes included myocardial infarction, ischemic stroke or cardiovascular death. RESULTS: Primary composite outcomes occurred in 54 patients in the sitagliptin group (26.3%) and in 164 patients in the comparison group (20.0%) (HR, 1.32; 95% CI, 0.97-1.79; P=0.079) during the mean follow-up of 1.02years (SD=0.71years). The sitagliptin group had similar risks of ischemic stroke, all-cause mortality or hospitalization for heart failure (HF) compared to the non-sitagliptin group (P=0.938, 0.523 and 0.795 respectively). However, sitagliptin use was associated with increased risks of recurrent myocardial infarction (HR, 1.73; 95% CI, 1.15-2.58; P=0.008) and percutaneous coronary revascularization (HR, 1.43; 95% CI, 1.04-1.95; P=0.026). CONCLUSIONS: Among type 2 diabetic patients with CKD after AMI, the use of sitagliptin was not associated with an increased risk of cardiovascular death, ischemic stroke or hospitalization for HF but was associated with increased risks of recurrent MI and percutaneous coronary revascularization.
BACKGROUND: The cardiovascular safety and efficacy of sitagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, in type 2 diabeticpatients with chronic kidney disease (CKD) after acute myocardial infarction (AMI) are unclear. METHODS: We analyzed data from the Taiwan National Health Insurance Research Database between March 1st, 2009 and December 31st, 2011. A total of 1025 AMI patients with diabetes with chronic kidney disease were selected as the study cohort. The study evaluated the cardiovascular safety and efficacy of sitagliptin by comparing 205 subjects (20%) who use sitagliptin to 820 matched subjects (80%) who do not. The primary outcomes included myocardial infarction, ischemic stroke or cardiovascular death. RESULTS: Primary composite outcomes occurred in 54 patients in the sitagliptin group (26.3%) and in 164 patients in the comparison group (20.0%) (HR, 1.32; 95% CI, 0.97-1.79; P=0.079) during the mean follow-up of 1.02years (SD=0.71years). The sitagliptin group had similar risks of ischemic stroke, all-cause mortality or hospitalization for heart failure (HF) compared to the non-sitagliptin group (P=0.938, 0.523 and 0.795 respectively). However, sitagliptin use was associated with increased risks of recurrent myocardial infarction (HR, 1.73; 95% CI, 1.15-2.58; P=0.008) and percutaneous coronary revascularization (HR, 1.43; 95% CI, 1.04-1.95; P=0.026). CONCLUSIONS: Among type 2 diabeticpatients with CKD after AMI, the use of sitagliptin was not associated with an increased risk of cardiovascular death, ischemic stroke or hospitalization for HF but was associated with increased risks of recurrent MI and percutaneous coronary revascularization.
Authors: Mugdha Gokhale; John B Buse; Michele Jonsson Funk; Jennifer Lund; Virginia Pate; Ross J Simpson; Til Stürmer Journal: Diabetes Obes Metab Date: 2017-03-17 Impact factor: 6.577
Authors: Sengwee Toh; Christian Hampp; Marsha E Reichman; David J Graham; Suchitra Balakrishnan; Frank Pucino; Jack Hamilton; Samuel Lendle; Aarthi Iyer; Malcolm Rucker; Madelyn Pimentel; Neesha Nathwani; Marie R Griffin; Nancy J Brown; Bruce H Fireman Journal: Ann Intern Med Date: 2016-04-26 Impact factor: 25.391
Authors: Carlo B Giorda; Roberta Picariello; Barbara Tartaglino; Lisa Marafetti; Fabiana Di Noi; Annalisa Alessiato; Giuseppe Costa; Roberto Gnavi Journal: BMJ Open Date: 2015-06-05 Impact factor: 2.692
Authors: Ling Li; Sheyu Li; Ke Deng; Jiali Liu; Per Olav Vandvik; Pujing Zhao; Longhao Zhang; Jiantong Shen; Malgorzata M Bala; Zahra N Sohani; Evelyn Wong; Jason W Busse; Shanil Ebrahim; German Malaga; Lorena P Rios; Yingqiang Wang; Qunfei Chen; Gordon H Guyatt; Xin Sun Journal: BMJ Date: 2016-02-17